Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Fineline Cube Apr 30, 2026
Company Drug

BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer

Fineline Cube Apr 30, 2026
Hospital Policy / Regulatory

NHC Issues Notification on Medication Safety Management and Rational Drug Use

Fineline Cube Aug 8, 2022

The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and...

Company Deals

Ningbo Health Gene Raises Hundreds of Millions in Series C Financing

Fineline Cube Aug 8, 2022

Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised...

Company Medical Device

Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base

Fineline Cube Aug 8, 2022

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun...

Company

Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures

Fineline Cube Aug 8, 2022

Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...

Company Deals

Intellective Biologics Raises Over RMB500m in Series C Financing Round

Fineline Cube Aug 5, 2022

China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly...

Company Deals

MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development

Fineline Cube Aug 5, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...

Company Deals

invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19

Fineline Cube Aug 5, 2022

invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...

Company Drug

Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China

Fineline Cube Aug 5, 2022

US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...

Company

BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple

Fineline Cube Aug 5, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...

Company Deals

Innovent Biologics and Sanofi Announce License Deal for Drug Development in China

Fineline Cube Aug 5, 2022

China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...

Company

Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge

Fineline Cube Aug 5, 2022

US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...

Company

Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip

Fineline Cube Aug 5, 2022

Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration

Fineline Cube Aug 5, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...

Company Drug

Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment

Fineline Cube Aug 5, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study

Fineline Cube Aug 5, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...

Company Deals

HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization

Fineline Cube Aug 5, 2022

China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...

Company

Innovent Biologics’ Q2 2022 Revenues Surpass RMB 1 Billion, Seven Products Approved

Fineline Cube Aug 5, 2022

Innovent Biologics Inc. (HKG: 1801) released its Q2 2022 financial report, with product revenues exceeding...

Company Drug

Hybio Pharmaceutical’s HY3000 Nasal Spray for COVID-19 Enters NMPA Review

Fineline Cube Aug 5, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its clinical trial filing for HY3000...

Company

GenScript’s Legend Biotech Appoints Three New Directors to Board

Fineline Cube Aug 5, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that its subsidiary...

Company Drug Legal / IP

Boehringer Ingelheim Wins Patent Infringement Ruling Against HEC Over Trajenta

Fineline Cube Aug 4, 2022

The China National Intellectual Property Administration (CNIPA) has ruled in favor of German pharmaceutical giant...

Posts pagination

1 … 634 635 636 … 660

Recent updates

  • Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC
  • GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength
  • GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership
  • AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength
  • BeOne Medicines’ Tislelizumab-Zanidatamab Combo Receives FDA Priority Review for HER2-Positive Gastric Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Avistone Biotechnology’s Andatinib Receives China Conditional Approval for EGFR Ex20ins NSCLC

Company

GE Healthcare Reports 7.4% Q1 Revenue Growth to $5.1B Driven by Imaging and Pharmaceutical Diagnostics Strength

Company

GE Healthcare Restructures Imaging Business with $14.6B AIS Segment and New Executive Leadership

Others

AstraZeneca Reports 8% Q1 Revenue Growth to $15.3B Driven by Oncology and Rare Disease Strength

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.